Risk of Congenital Anomalies with Dolutegravir-Based Anti-retroviral Regimens: A Systematic Review and Meta-analysis

Overview

Journal Clin Drug Investig

Date 2024 Sep 20

PMID 39302585

Authors

Shuvasree Payra

Divya Harsha

Keshav Kumar

Pramod Kumar Manjhi

Shruti Singh

Rajesh Kumar

Sunil Kumar Singh

Alok Kumar

Vikas Maharshi

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Dolutegravir has been used as a first-line anti-human immunodeficiency virus drug because of its better efficacy compared with other counterpart medicines. However, making a unanimous decision on its use during pregnancy has become difficult for stakeholders following congenital anomalies reported with its use. The objective of this systematic review and meta-analysis was to study the risk of congenital anomalies in newborns exposed to dolutegravir-based-regimens compared with those exposed to non-dolutegravir-based regimens during the antenatal period.

Methods: An extensive literature search was performed in MEDLINE (through PubMed), EMBASE, Cochrane Database of Systematic Reviews, Google Scholar, and ClinicalTrials.gov until 30 November, 2023. Studies reporting data on congenital anomalies following antenatal use of dolutegravir were included. Risk of bias for randomized controlled trials, non-randomized controlled trials, and observational studies was assessed using RoB2, ROBINS-I, and ROBINS-E tools, respectively. A meta-analysis was performed in 'RevMan 5.4.1' using a random-effects model. Heterogeneity was assessed by the 'Q' statistic and I value. A sensitivity analysis was performed for higher heterogeneity/high-risk studies. The study protocol was registered in PROSPERO [CRD42023446374] a priori.

Results: Of 26 eligible studies, 12 (six randomized controlled trials and six observational studies with a pooled sample of 32,617) were included in a meta-analysis and 14 in a qualitative synthesis only. The meta-analysis does not show a statistically significant difference in the risk of congenital anomalies between newborns exposed antenatally to dolutegravir-based regimen(s) and those exposed to non-dolutegravir-based regimens [risk ratio 1.10; 95% confidence interval 0.79-1.53; p = 0.59]. Heterogeneity was moderate (I = 47%). Pooled results for randomized controlled trials and observational studies separately and the sensitivity analysis for heterogeneity provided similar results.

Conclusions: The risk of congenital anomalies was not significantly different between dolutegravir-based regimens and non-dolutegravir-based-regimens in newborns exposed during their antenatal period.

References

Zdanowicz M . The pharmacology of HIV drug resistance. Am J Pharm Educ. 2006; 70(5):100. PMC: 1637011. DOI: 10.5688/aj7005100. View

Williams P, Crain M, Yildirim C, Hazra R, Van Dyke R, Rich K . Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr. 2014; 169(1):48-55. PMC: 4286442. DOI: 10.1001/jamapediatrics.2014.1889. View

Alemu F, Yalew A . Does antiretroviral therapy cause congenital malformations? A systematic review and meta-analysis. Epidemiol Health. 2021; 43:e2021008. PMC: 8060528. DOI: 10.4178/epih.e2021008. View

The Lancet Hiv . End resistance to dolutegravir roll-out. Lancet HIV. 2020; 7(9):e593. DOI: 10.1016/S2352-3018(20)30231-9. View

Llibre J, Pulido F, Garcia F, Garcia Deltoro M, Blanco J, Delgado R . Genetic barrier to resistance for dolutegravir. AIDS Rev. 2014; 17(1):56-64. View

Patel K, Huo Y, Jao J, Powis K, Williams P, Kacanek D . Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States. N Engl J Med. 2022; 387(9):799-809. PMC: 9744124. DOI: 10.1056/NEJMoa2200600. View

Dontsova V, Mohan H, Blanco C, Jao J, Greene N, Copp A . Metabolic implications and safety of dolutegravir use in pregnancy. Lancet HIV. 2023; 10(9):e606-e616. PMC: 11100098. DOI: 10.1016/S2352-3018(23)00141-8. View

Zash R, Jacobson D, Diseko M, Mayondi G, Mmalane M, Essex M . Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. Lancet Glob Health. 2018; 6(7):e804-e810. PMC: 6071315. DOI: 10.1016/S2214-109X(18)30218-3. View

Dorward J, Sookrajh Y, Khubone T, van der Molen J, Govender R, Phakathi S . Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study. Lancet HIV. 2023; 10(5):e284-e294. PMC: 10288006. DOI: 10.1016/S2352-3018(23)00047-4. View

10.

Zash R, Makhema J, Shapiro R . Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. N Engl J Med. 2018; 379(10):979-981. PMC: 6550482. DOI: 10.1056/NEJMc1807653. View

11.

Bornhede R, Soeria-Atmadja S, Westling K, Pettersson K, Naver L . Dolutegravir in pregnancy-effects on HIV-positive women and their infants. Eur J Clin Microbiol Infect Dis. 2018; 37(3):495-500. DOI: 10.1007/s10096-018-3195-9. View

12.

Mulligan N, Best B, Wang J, Capparelli E, Stek A, Barr E . Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018; 32(6):729-737. PMC: 5854536. DOI: 10.1097/QAD.0000000000001755. View

13.

Grayhack C, Sheth A, Kirby O, Davis J, Sibliss K, Nkwihoreze H . Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy. AIDS. 2018; 32(14):2017-2021. PMC: 6125741. DOI: 10.1097/QAD.0000000000001931. View

14.

van De Ven N, Pozniak A, Levi J, Clayden P, Garratt A, Redd C . Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy. Clin Infect Dis. 2019; 70(12):2599-2606. DOI: 10.1093/cid/ciz684. View

15.

Saint-Lary L, Diallo A, de Monteynard L, Paul C, Marchand L, Tubiana R . In utero exposure to antiretroviral drugs and pregnancy outcomes: Analysis of the French ANRS pharmacovigilance database. Br J Clin Pharmacol. 2021; 88(3):942-964. DOI: 10.1111/bcp.15075. View

16.

Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B . Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLoS Med. 2019; 16(9):e1002895. PMC: 6754125. DOI: 10.1371/journal.pmed.1002895. View

17.

Zash R, Holmes L, Diseko M, Jacobson D, Brummel S, Mayondi G . Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med. 2019; 381(9):827-840. PMC: 6995896. DOI: 10.1056/NEJMoa1905230. View

18.

Money D, Lee T, OBrien C, Brophy J, Bitnun A, Kakkar F . Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study. BJOG. 2019; 126(11):1338-1345. DOI: 10.1111/1471-0528.15838. View

19.

Chouchana L, Beeker N, Treluyer J . Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?. J Acquir Immune Defic Syndr. 2019; 81(4):481-486. DOI: 10.1097/QAI.0000000000002065. View

20.

Venter W, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N . Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised,.... Lancet HIV. 2020; 7(10):e666-e676. DOI: 10.1016/S2352-3018(20)30241-1. View